Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Diagnosing and managing metabolic dysfunction-associated steatotic liver disease (MASLD) remains a major challenge in primary care due to lack of agreement on diagnostic tools, difficulty in identifying symptoms and determining their cause, absence of approved pharmacological treatments, and limited awareness of the disease. However, prompt diagnosis and management are critical to preventing MASLD from progressing to more severe forms of liver disease. This highlights the need to raise awareness and improve understanding of MASLD among both patients and physicians. The patient perspective is invaluable to advancing our knowledge of this disease and how to manage it, as their perspectives have led to the growing recognition that patients experience subtle symptoms and that patient-reported outcomes should be incorporated into drug development. This review and expert opinion examine MASLD and metabolic dysfunction-associated steatohepatitis from the patient and physician perspective from pre-diagnosis to diagnosis and early care, through to progression to advanced liver damage. Specifically, the paper dives into the issues patients and physicians experience, and, in turn, what is required to improve diagnosis and management, including tips and tools to empower patients and physicians dealing with MASLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationEASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
Eslam, M., Sanyal, A. J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., Kleiner, D. E., Brunt, E., Bugianesi, E., Yki-Järvinen, H., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.312 · Cited by 3,286
Self-citationAngulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437739.71477.ee · Cited by 2,735
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287
Younossi, Z. M., Golabi, P., de Avila, L., Paik, J. M., Srishord, M., Fukui, N., Qiu, Y., Burns, L., Afendy, A., & Nader, F. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.021 · Cited by 2,235
Berzigotti, A., Tsochatzis, E., Boursier, J., Castera, L., Cazzagon, N., Friedrich-Rust, M., Petta, S., & Thiele, M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.025 · Cited by 1,925
Singh, S., Allen, A. M., Wang, Z., Prokop, L. J., Murad, M. H., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.014 · Cited by 1,748 · cited 1×
“A retrospective analysis of observational clinical trials estimated that one-third of patients with MASLD develop progressive fibrosis, just under half remained stable, and fibrosis improved in one-fifth of patients [27].”
Self-citationRandomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis
Promrat, K., Kleiner, D. E., Niemeier, H. M., Jackvony, E., Kearns, M., Wands, J. R., Fava, J. L., & Wing, R. R. (2010) · Hepatology · doi:10.1002/hep.23276 · Cited by 1,330
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
Sanyal, A. J., Van Natta, M. L., Clark, J., Neuschwander-Tetri, B. A., Diehl, A., Dasarathy, S., Loomba, R., Chalasani, N., Kowdley, K., Hameed, B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2029349 · Cited by 1,146 · cited 2×
“A prospective multicenter study estimated the incidence rate of deaths from any cause at 0.32 deaths per 100 person-years for stage F0–F2, rising to 0.89 deaths per 100 persons-years for stage F3 and 1.76 deaths per 100 person-years for stage F4 in patients with MASLD [29].”
InfluentialSelf-citationTaylor, R. S., Taylor, R. J., Bayliss, S., Hagström, H., Nasr, P., Schattenberg, J. M., Ishigami, M., Toyoda, H., Wai-Sun Wong, V., Peleg, N., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.043 · Cited by 1,069
Self-citationA multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2024) · Annals of Hepatology · doi:10.1016/j.aohep.2023.101133 · Cited by 844
Self-citationAdvancing the global public health agenda for NAFLD: a consensus statement
Lazarus, J. V., Mark, H. E., Anstee, Q. M., Arab, J. P., Batterham, R. L., Castera, L., Cortez-Pinto, H., Crespo, J., Cusi, K., Dirac, M. A., et al. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00523-4 · Cited by 757
Self-citation2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis
Le, M. H., Yeo, Y. H., Li, X., Li, J., Zou, B., Wu, Y., Ye, Q., Huang, D. Q., Zhao, C., Zhang, J., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.12.002 · Cited by 711 · cited 1×
“MASLD affects 25–30% of the global population [16,17], with prevalence ranging from 13.”
Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort
Simon, T. G., Roelstraete, B., Khalili, H., Hagström, H., & Ludvigsson, J. F. (2021) · Gut · doi:10.1136/gutjnl-2020-322786 · Cited by 673
Lassailly, G., Caiazzo, R., Ntandja-Wandji, L.-C., Gnemmi, V., Baud, G., Verkindt, H., Ningarhari, M., Louvet, A., Leteurtre, E., Raverdy, V., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.06.006 · Cited by 622
Thoma, C., Day, C. P., & Trenell, M. I. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.06.010 · Cited by 523 · cited 2×
“In contrast, if physicians tell patients that they have a disease, they may be more proactive in making lifestyle changes that could delay disease progression [74–76].”
Association of histologic disease activity with progression of nonalcoholic fatty liver disease
Kleiner, D. E., Brunt, E. M., Wilson, L. A., Behling, C., Guy, C., Contos, M., Cummings, O., Yeh, M., Gill, R., Chalasani, N., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.12565 · Cited by 372 · cited 1×
“In a prospective cohort study in patients with MASLD and MASH, fibrosis was reported to progress by ≥ 1 stage in 33.9% and regress by ≥ 1 stage in 30.0% [28].”
InfluentialSelf-citationLazo, M., Solga, S. F., Horska, A., Bonekamp, S., Diehl, A. M., Brancati, F. L., Wagenknecht, L. E., Pi-Sunyer, F. X., Kahn, S. E., Clark, J. M., et al. (2010) · Diabetes Care · doi:10.2337/dc10-0856 · Cited by 367
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s004 · Cited by 285
Gepner, Y., Shelef, I., Komy, O., Cohen, N., Schwarzfuchs, D., Bril, N., Rein, M., Serfaty, D., Kenigsbuch, S., Zelicha, H., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.04.013 · Cited by 236
Polyzos, S. A., & Margioris, A. N. (2018) · Hormones · doi:10.1007/s42000-018-0049-x · Cited by 212 · cited 1×
“Fatigue, which may be related to sarcopenia in some patients [47,48], is another symptom commonly reported, even in the early stages of MASLD, and negatively impacts HRQoL [49–51].”
Younossi, Z. M., Anstee, Q. M., Wai-Sun Wong, V., Trauner, M., Lawitz, E. J., Harrison, S. A., Camargo, M., Kersey, K., Subramanian, G. M., Myers, R. P., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.12.003 · Cited by 118 · cited 1×
“Nonetheless, emerging evidence shows patient-reported outcomes, such as HRQoL, are associated with histological and clinical features of MASLD and MASH [57,84].”
VILAR GOMEZ, E., RODRIGUEZ DE MIRANDA, A., GRA ORAMAS, B., ARUS SOLER, E., LLANIO NAVARRO, R., CALZADILLA BERTOT, L., YASELLS GARCIA, A., & DEL ROSARIO ABREU VAZQUEZ, M. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04122.x · Cited by 105
Cited by
Sakuma, I., Gaspar, R. C., Nasiri, A. R., Dufour, S., Kahn, M., Zheng, J., LaMoia, T. E., Guerra, M. T., Taki, Y., Kawashima, Y., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2502978122 · Cited by 46
(2025) · doi:10.1101/2025.02.25.640203 · Cited by 45
Basic and translational evidence supporting the role of TM6SF2 in VLDL metabolism
Liu, J., Ginsberg, H. N., & Reyes-Soffer, G. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000930 · Cited by 19
The role of matrix metalloproteinases in liver function and disease
Mitropoulou, G., Kompoura, V., Saffioti, F., & Mavroeidis, V. K. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl27127 · Cited by 14
Metadata
- Authors
- Eskridge, W., Cryer, D. R., Schattenberg, J. M., Gastaldelli, A., Malhi, H., Allen, A. M., Noureddin, M., & Sanyal, A. J.
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2023-09-26
- Volume
- 12
- Issue
- 19
- Pages
- 6216
- ISSN
- 2077-0383 (ISSN-L)
- OpenAlex
- W4387060269
- Cited by
- 111
- References
- 27
- FWCI
- 18.56
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.